Private medicine has already captured 25% of the Russian medical services market in monetary terms, its share expected to grow to 30% by 2030. The volume of the commercial segment reached approximately 2.4 trillion rubles in 2025, according to a study by the consulting company Kept.
“The study data align with our observations: private medicine is growing, and this is a sustainable trend,” notes Roman Mironchik, co-owner of the INVITRO holding.
In terms of consolidation and organic growth, both processes are proceeding simultaneously. Room for organic growth remains in the regions, since the penetration of private medicine in million-plus cities and in smaller towns differs radically. Large chains continue to enter smaller cities and develop “untapped territories,” the expert explains.
At the same time, the market is consolidating: expensive equipment, personnel shortages, and digitalization requirements complicate life for smaller players, and many of them become M&A targets for federal chains – this is faster and often cheaper than organic construction from scratch.
“The share of top players will continue to grow in the coming years,” Roman Mironchik forecasts. “The fastest growth will be in laboratory and instrumental diagnostics – the least capital-intensive format for scaling – as well as cancer diagnostics; reproductive medicine, gynecology and urology against the backdrop of the current demographic agenda; pediatrics; telemedicine and hybrid formats (at-home testing plus online consultation); check-ups and corporate health programs.”
According to Roman Mironchik’s assessment, the laboratory segment is one of the most mature and dynamic. Consolidation is also underway here: federal chains are acquiring regional laboratories for economies of scale. The share of complex, high-margin testing such as genetic testing, tumor markers, reproductive panels is growing against the backdrop of price pressure on basic tests. Competition with marketplaces and aggregators is intensifying, pushing laboratories to develop their own digital channels. Expansion into medium-sized and small cities continues, where private laboratories fill the niche faster than full-cycle clinics. By 2030, the share of private medicine may approach 30%, and laboratory diagnostics will remain one of the main drivers of this growth, the expert concludes.